• Niranjan Shiwaji Khaire, Nishant Jindal, Lakshmi Narayana Yaddanapudi, Suchet Sachdev, Rekha Hans, Naresh Sachdeva, Mini P Singh, Anup Agarwal, Aparna Mukherjee, Gunjan Kumar, Ratti Ram Sharma, Vikas Suri, Goverdhan Dutt Puri, and Pankaj Malhotra.
• Department of Internal Medicine, Postgraduate Institute of Medical Education & Research, Chandigarh, India.
• Indian J Med Res. 2021 Jan 1; 153 (1 & 2): 648564-85.

AbstractConvalescent plasma (CP) therapy is one of the promising therapies being tried for COVID-19 patients. This passive immunity mode involves separating preformed antibodies against SARS-CoV-2 from a recently recovered COVID-19 patient and infusing it into a patient with active disease or an exposed individual for prophylaxis. Its advantages include ease of production, rapid deployment, specificity against the target infectious agent, and scalability. In the current pandemic, it has been used on a large scale across the globe and also in India. However, unequivocal proof of efficacy and effectiveness in COVID-19 is still not available. Various CP therapy parameters such as donor selection, antibody quantification, timing of use, and dosing need to be considered before its use. The current review attempts to summarize the available evidence and provide recommendations for setting up CP protocols in clinical and research settings.

17 keywords...

hide…